Clinical trials: Phase I
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma
Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer
This phase II single-arm pilot study will evaluate the safety and preliminary efficacy of Optune-Tumor Treating Fields (TTFields) therapy as a prophylactic approach to reducing small cell lung cancer (SCLC) that has spread to the…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8
- Trial name
- NCT03995667
- Testing
- Questionnaire Administration, Tumor Treating Fields Therapy
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- OHSU Knight Cancer Institute
Healthy
A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers
Drug-drug interaction study; to examine the pharmacokinetics of SPD503 and VYVANSE (lisdexamfetamine dimesylate) when given alone, and in combination.
- Trial name
- NCT00919867
- Testing
- SPD503, VYVANSE, SPD503 and VYVANSE
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shire
Triple Negative Metastatic Breast Cancer, BRCA-mutated Solid Tumor
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
Open label, non-randomized, dose escalation and expansion Phase Ia/b trial to evaluate the safety of the combination of BMN 673 and carboplatin, and subsequently BMN 673 in combination with paclitaxel and carboplatin to determine…
- Trial name
- NCT02358200
- Testing
- BMN-673, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Pamela Munster
Sarcoma, Cervical Cancer
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
The present trial is an open, single-arm phase I clinical study aimed at assessing the safety, tolerability, viral distribution and shedding patterns, pharmacodynamics, immunogenicity, and antitumor efficacy of GC001 oncolytic…
- Conditions
- Sarcoma, Cervical Cancer, Colon Cancer, Lung Cancer
- Trial name
- NCT06508307
- Testing
- A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors
- Where
- China
- Volunteers
- 21 people
- Sponsor
- GONGCHU Biotechnology Co., Ltd
Antibody Mediated Rejection of Lung Transplant
A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung Transplantation
Antibody-mediated rejection after lung transplantation commonly results in allograft failure and death in spite of current therapeutic regimens.
- Trial name
- Siltux-AMR (NCT06990711)
- Testing
- Siltuximab
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Washington University School of Medicine
Brain and Central Nervous System Tumors, Leukemia
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment
RATIONALE: Drugs used in chemotherapy, such as talotrexin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Brain and Central Nervous System Tumors, Leukemia, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00458744
- Testing
- talotrexin, chemotherapy
- Sponsor
- Children's Oncology Group
Gastroesophageal Junction, Gastroesophageal Adenocarcinoma
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This is a phase 1/2, multicenter, open-label umbrella platform study that will evaluate the safety and tolerability of investigational agents with pembrolizumab and fluoropyrimidine chemotherapy for the first-line (1L) treatment…
- Conditions
- Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
- Trial name
- NCT06469944
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan (sac-TMT), Capecitabine
- Where
- 50 sites in United States, Brazil and 10 more
- Volunteers
- 160 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia-Lymphoma, Adult T-Cell
EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma
The rationale of the current study is to explore the use of combination chemotherapy together with antiretroviral agents in order to determine the efficacy and toxicity of this approach, while also examining markers of virus…
- Trial name
- ATLL (NCT01000285)
- Testing
- Bortezomib, Etoposide, Vincristine
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Systemic Lupus Erythematosus
Safety of IFNa Kinoid in Systemic Lupus Erythematosus
Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attractive therapeutic strategy.
- Trial name
- NCT01058343
- Testing
- IFN-K
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 28 people
- Sponsor
- Neovacs
Healthy
Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants
The purpose of this study is to determine the effect of a high-fat, high-caloric meal on the pharmacokinetics (PK) of acoramidis in healthy adult participants following an oral single dose administration of acoramidis.
- Trial name
- NCT04958135
- Testing
- Acoramidis
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Advanced Solid Tumor
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Trial name
- NCT06833008
- Testing
- IPN01195
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 42 people
- Sponsor
- Ipsen
Alzheimer's Disease, Mild Cognitive Impairment
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
This is a first-in-human clinical trial to test whether a protein administered into the brain continuously by gene therapy, Brain-Derived Neurotrophic Factor (BDNF), will slow or prevent cell loss in the brains of people affected…
- Trial name
- NCT05040217
- Testing
- AAV2-BDNF Gene Therapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mark Tuszynski
Non Small Cell Lung Cancer
Phase I Combination Ixabepilone + Cisplatin
The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the…
- Trial name
- NCT00832117
- Testing
- Ixabepilone, Cisplatin
- Where
- 7 sites in United States, Italy
- Volunteers
- 30 people
- Sponsor
- R-Pharm
Fallopian Tube Cancer, Ovarian Cancer
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of CT-2103 in treating patients who have recurrent…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00017017
- Testing
- paclitaxel poliglumex
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Healthy
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers
Primary - To investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous dosage form of LCB01-0371 comparing to oral dosage in Healthy Male Volunteers Secondary To investigate the absolute bio availability of…
- Trial name
- NCT02882789
- Testing
- LCB01-0371, LCB01-0371 400mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LigaChem Biosciences, Inc.
Pancreatic Tumor, Benign, Pancreatic Neoplasms
Laser Tissue Welding - Distal Pancreatectomy Sealing Study
The laser tissue welding device is intended for use in patients requiring sealing of the pancreas after partial pancreatectomy, and including those patients who are fully heparinized or have hemodilutional coagulation failure.
- Conditions
- Pancreatic Tumor, Benign, Pancreatic Neoplasms, Pancreatic Adenocarcinoma, Pancreatic Pseudocyst
- Trial name
- LTW (NCT03147768)
- Testing
- Distal Pancreatectomy Sealing Using LTW
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Laser Tissue Welding, Inc.
Melanoma (Skin), Neuroblastoma
Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors
RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein use different ways to stimulate the immune system and stop cancer cells from growing.
- Conditions
- Melanoma (Skin), Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- NCT00003750
- Testing
- hu14.18-IL2 fusion protein
- Where
- 59 sites in United States, Australia and 1 more
- Volunteers
- 28 people
- Sponsor
- Children's Oncology Group
Advanced Solid Tumor
Study to Assess AFM24 in Advanced Solid Cancers
AFM24-101 is a first in human Phase 1/2a open-label, non-randomized, multi-center, multiple ascending dose escalation/expansion study evaluating AFM24 as monotherapy in patients with advanced solid malignancies whose disease has…
- Trial name
- NCT04259450
- Testing
- 14 mg AFM24, 40 mg AFM24, 80 mg AFM24
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 85 people
- Sponsor
- Affimed GmbH
Advanced Solid Tumor
Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies
To estimate the maximum tolerated dose (MTD) or recommended dose for phase II (RP2D) of CLR457 and to investigate the anti-tumor activity of CLR457
- Trial name
- NCT02189174
- Testing
- CLR457
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.